Celyad Oncology SA (EBR:CYAD)
Belgium · Delayed Price · Currency is EUR 0.2000
-0.0300 (-13.04%)
Oct 9, 2026, 5:39 PM CET
Celyad Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.01 | 0.02 | 0.19 | 0.1 | - | - | |
Revenue Growth | -96.24% | -88.71% | 82.35% | 1940.00% | - | - |
Cost of Revenue | -0.23 | 0.01 | 0.01 | 0.07 | - | - |
Gross Profit | 0.24 | 0.01 | 0.17 | 0.03 | - | - |
Selling, General & Admin | 2.79 | 3.78 | 3.2 | 6.25 | 10.56 | 10 |
Research & Development | 3.42 | 3.42 | 3.24 | 4.38 | 18.91 | 20.69 |
Other Operating Expenses | -6.74 | -5.66 | -0.39 | -1.05 | -4.03 | -3.44 |
Operating Expenses | -0.7 | 1.54 | 6.04 | 9.58 | 25.45 | 27.24 |
Operating Income | 0.93 | -1.53 | -5.87 | -9.54 | -25.45 | -27.24 |
Interest Expense | -0.04 | -0.06 | -0.1 | -0.08 | -0.2 | -0.26 |
Interest & Investment Income | - | 0.01 | 0.15 | 0.03 | 0.01 | 0.03 |
Currency Exchange Gain (Loss) | - | - | -0.02 | - | 0.17 | 0.01 |
Other Non Operating Income (Expenses) | 0 | 0 | -0 | - | -0 | 0.11 |
EBT Excluding Unusual Items | 0.89 | -1.58 | -5.84 | -9.6 | -25.46 | -27.35 |
Impairment of Goodwill | - | - | - | - | -0.64 | - |
Gain (Loss) on Sale of Assets | 2.31 | 2.31 | 0.01 | 1.09 | 5 | -0 |
Asset Writedown | - | - | - | - | -34.44 | - |
Other Unusual Items | 0.1 | 0.1 | - | - | 14.68 | 0.85 |
Pretax Income | 3.3 | 0.83 | -5.82 | -8.51 | -40.87 | -26.5 |
Income Tax Expense | - | - | - | -0.06 | 0.07 | 0.01 |
Net Income | 3.3 | 0.83 | -5.82 | -8.45 | -40.94 | -26.51 |
Net Income to Common | 3.3 | 0.83 | -5.82 | -8.45 | -40.94 | -26.51 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 44 | 43 | 41 | 26 | 23 | 16 |
Shares Outstanding (Diluted) | 48 | 46 | 41 | 26 | 23 | 16 |
Shares Change | 15.71% | 11.68% | 61.06% | 13.84% | 44.80% | 11.92% |
EPS (Basic) | 0.07 | 0.02 | -0.14 | -0.33 | -1.81 | -1.70 |
EPS (Diluted) | 0.07 | 0.02 | -0.14 | -0.33 | -1.81 | -1.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -5.11 | -6.9 | -5.68 | -16.1 | -28.13 | -26.97 |
Free Cash Flow Per Share | -0.11 | -0.15 | -0.14 | -0.63 | -1.25 | -1.73 |
Gross Margin | 3357.14% | 61.91% | 93.55% | 32.35% | - | - |
Operating Margin | 13300.00% | -7261.90% | -3155.38% | -9356.86% | - | - |
Profit Margin | 47071.43% | 3952.38% | -3131.18% | -8282.35% | - | - |
Free Cash Flow Margin | -72957.14% | -32857.14% | -3053.76% | -15785.29% | - | - |
EBITDA | 0.78 | -1.52 | -5.69 | -9.04 | -24.74 | -26.68 |
EBITDA Margin | 11071.43% | - | - | - | - | - |
D&A For EBITDA | -0.16 | 0.01 | 0.18 | 0.51 | 0.71 | 0.56 |
EBIT | 0.93 | -1.53 | -5.87 | -9.54 | -25.45 | -27.24 |
EBIT Margin | 13300.00% | - | - | - | - | - |